Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Encompass Health Corporation’s (NYSE: EHC) SEC filings, offering detailed insight into the company’s inpatient rehabilitation hospital business and financial profile. As the largest owner and operator of inpatient rehabilitation hospitals in the United States, Encompass Health uses its filings to report operating results, liquidity measures and other material information.
Current reports on Form 8-K included in the available information show how the company discloses quarterly financial results, updates to full-year guidance and investor materials. These filings reference metrics such as net operating revenue, Adjusted EBITDA, adjusted earnings per share, leverage ratio and adjusted free cash flow, along with explanations of why non-GAAP measures are used and how they are reconciled to comparable GAAP figures.
Other 8-K filings address topics like publication of an Investor Reference Book, which provides an overview of the company and its industry, business outlook, growth strategy and operational initiatives, as well as Regulation FD communications when senior management meets with investors and analysts. Governance-related 8-Ks can also appear, such as notices of director departures.
Through this filings page, users can review Encompass Health’s earnings-related 8-Ks, Regulation FD disclosures and other material event reports as they are made available via EDGAR. AI-powered tools on the platform can help summarize lengthy documents, highlight key metrics and clarify definitions of non-GAAP measures like Adjusted EBITDA and adjusted free cash flow, making it easier to understand how the company evaluates performance, manages leverage and plans for growth.
For anyone analyzing EHC stock, these SEC filings are a primary source for understanding Encompass Health’s financial condition, risk disclosures, capital structure and strategic communications with investors.
Encompass Health Corporation reported a change on its board of directors. On September 17, 2025, director Patricia Maryland informed the company that she is retiring from the board for health reasons, effective immediately. The filing notes the board’s appreciation for her insights and contributions, as expressed by chairman Greg Carmichael.
Encompass Health Corp provided forward-looking non-GAAP guidance in an Item 7.01 disclosure, projecting net operating revenue of $5,880 million to $5,980 million, Adjusted EBITDA of $1,220 million to $1,250 million, and adjusted earnings per share from continuing operations of $5.12 to $5.34. The company states it does not provide comprehensive GAAP guidance because certain items cannot be reliably predicted, but it estimates 2025 interest expense and amortization of debt discounts and fees of approximately $125 million and amortization of debt-related items of approximately $10 million. The disclosure is furnished under Regulation FD and is not deemed "filed" for Section 18 purposes.
Encompass Health Corp (EHC) insider Patrick W. Tuer, EVP and Chief Operating Officer, reported a sale of 1,020 shares of Encompass Health common stock on 08/27/2025 at a reported price of $123.59 per share. After the transaction, Mr. Tuer beneficially owned 18,846 shares. The Form 4 was signed by an attorney-in-fact, Patrick Darby, on behalf of the reporting person.
Encompass Health Corporation (EHC) Form 144 reports a proposed sale of 1,020 common shares via UBS Financial Services on the NYSE, with an aggregate market value of $126,061.80. The shares were acquired through restricted stock unit vesting in January–February 2023 (individual lots of 218, 290, 233 and 279 shares) and are scheduled for sale on 08/27/2025. The filer certifies no undisclosed material adverse information and provides no reportable sales in the prior three months.
Douglas E. Coltharp, EVP & Chief Financial Officer of Encompass Health Corporation (EHC), reported multiple non‑derivative transactions on 08/21/2025. The filing shows transfers involving common stock: 27,480 shares were disposed of by the reporting person’s spouse and simultaneously 27,480 shares were acquired by an irrevocable trust in which the reporting person is a beneficiary. After these moves the reporting person reports 37,749 shares beneficially owned via spouse and 125,631 shares indirectly held by an irrevocable trust for the benefit of children; the reporting person disclaims beneficial ownership of the spouse‑held shares. The report was signed by an attorney‑in‑fact.
Encompass Health Corporation (EHC) Q2 2025 condensed summary
Net operating revenues for the three months ended June 30, 2025 were $1,457.7 million (up 12.0% vs. Q2 2024) and $2,913.1 million for the six months ended June 30, 2025 (up 11.3% vs. prior year six months). Net income was $184.9 million for Q2 2025 and net income attributable to Encompass Health was $142.1 million for Q2 2025 vs. $114.1 million in Q2 2024. Diluted EPS for the quarter was $1.39. Adjusted EBITDA was $318.6 million for Q2 2025 and $632.2 million for the six months. Operating cash flow for six months was $558.8 million. Cash, cash equivalents, and restricted cash at June 30, 2025 were $137.4 million.
The company operated 168 inpatient rehabilitation hospitals as of June 30, 2025, completed a May 2025 acquisition of a Fort Myers inpatient rehabilitation unit (51% interest) with $19.0 million goodwill recorded, and continued shareholder distributions via repurchases ($56.8 million YTD) and dividends ($35.1 million YTD). Management estimates certain provisions of the One Big Beautiful Bill Act will produce approximately $180 million of current deductions, yielding an estimated $50 million in cash tax savings in 2025. The filing discloses ongoing Medicare Review Choice Demonstration (RCD) non-affirmations in Alabama cycles and other regulatory risks.